Nasdaq

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral ...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
EurekAlert!

Determining the structure of a molecule with laser-induced electron diffraction

Light microscopes have revolutionized our understanding of the microcosmos, but their resolution is limited to about 100 nanometers. To see how molecules bond, break, or change their structure, we ...
Seeking Alpha

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Nasdaq

Structure Therapeutics Inc. Announces Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions

Structure Therapeutics to present promising data on ACCG-2671 for obesity and GLP-1 receptor agonists for Parkinson's at ADA 2025. Structure Therapeutics announced two late-breaking poster ...